Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT07587242 is registered in ClinicalTrials.gov with Avidity Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping
- Lead sponsor
- Avidity Biosciences, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 1, 2026
- Completion date
- July 31, 2030
- Enrollment
- 70 (estimated)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.
congenital, dmd, duchene muscular dystrophy, genetic diseases, hereditary, muscular disease, muscular disorders, atrophic, muscular dystrophies, muscular dystrophies (duchenne, becker, myotonic dystrophy), musculoskeletal diseases, neonatal disease, nervous system diseases, neuromuscular diseases (nmd), x-linked